Abiopharma

🔍 Stengone Carmine N. (Director)

Company: Contineum Therapeutics, Inc. (CTNM)

Report Date: 2026-08-03

Detailed Transactions and Holdings:

• Acquired 2,500 shares of Class A Common Stock at $1.01 per share (Direct)
  Date: 2026-08-03 | Code: M | equity_swap_involved: 0 | shares_owned_after: 19,717.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 2,500 shares of Class A Common Stock at $16.0116 per share (Direct)
  Date: 2026-08-03 | Code: S | equity_swap_involved: 0 | shares_owned_after: 17,217.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 2,500 shares of Stock Option (right to buy) at $1.01 per share (Derivative)
  Date: 2026-08-03 | Code: M | Expires: 2030-02-24 | equity_swap_involved: 0 | shares_owned_after: 276,930.00 | transaction_form_type: 4 | Footnotes: F1, F3

Footnotes:

• F1: These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.06, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
• F3: Options granted under the Issuer's 2012 Equity Incentive Plan (the "Plan"). The option is fully vested.